Purdue, Ranbaxy Settle IP Fight Over Generic Oxycontin

Law360, New York (January 9, 2013, 6:51 PM EST) -- Ranbaxy Laboratories Ltd. has admitted to infringing three Purdue Pharma LP patents and agreed to waive possible antitrust claims under a deal to resolve litigation over the painkiller Oxycontin, which won approval from a New York federal judge Tuesday.   

Three patents asserted by Purdue were infringed by the filing of Ranbaxy applications for U.S. regulatory approval to make and sell generic oxycodone hydrochloride extended release tablets before Purdue's patents expired, said a consent judgment signed by U.S. District Judge Sidney H. Stein.

The judgment, which references...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.